Inhalation CDMO Vectura has announced an agreement to provide preclinical development services for Incannex Healthcare’s IHL-216A CBD/isoflurane, which Incannex is developing for the treatment of traumatic brain injury. In addition to performing screening, stability, and optimization studies, Vectura will manufacture the IHL-216A needed for toxicology studies. Monash University is conducting an in vivo study of IHL-216A for protection against sports concussion, and Vectura will develop the IHL-216A formulation alongside that study.
Incannex’s Chief Scientific Officer Mark Bleackley commented, “The in vivo study we have developed offers the opportunity to accelerate this program through to clinical development, and we look forward to working with Vectura, leveraging its wealth of experience in developing inhaled drugs, to progress this treatment to the next stage.”
Vectura Chief Commercial Officer Mark Bridgewater said, “The risks associated with head injuries in sport are becoming more widely recognized, and this project is at the forefront of research to not only make sports safer, but reduce the morbidity and mortality rates of people suffering serious head traumas. There are currently no pharmaceutical agents approved for the treatment of TBI, and we look forward to working with Incannex to develop a truly innovative and potentially life-saving drug.”
Vectura recently announced that it would be acquired by the Carlyle Group.
Read the Vectura press release.
